| Assessment Status | Awaiting HTA submission from Applicant |
| HTA ID | 21021 |
| Drug | Selparcatinib |
| Brand | Retsevmo® |
| Indication | For the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 08/06/2021 |
| Rapid review completed | 29/06/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 22/07/2021 |
| Pre-submission consultation with Applicant | 11/01/2022 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.
